TY - JOUR
T1 - Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology
T2 - From the Dallas Heart Study
AU - Grodin, Justin L
AU - Powell-Wiley, Tiffany M.
AU - Ayers, Colby R.
AU - Kumar, Darpan S.
AU - Rohatgi, Anand K
AU - Khera, Amit
AU - McGuire, Darren K
AU - de Lemos, James A
AU - Das, Sandeep R
N1 - Funding Information:
Justin L Grodin, none declared; Tiffany M Powell-Wiley, none declared; Colby R Ayers, none declared; Darpan S Kumar, none declared; Anand Rohatgi, none declared; Amit Khera, none declared; Darren K McGuire, consulting income from Tethys Bioscience; James A de Lemos, Grant support from Alere, Inc. and Roche Diagnostics, consulting income from Johnson and Johnson and Tethys Bioscience; Sandeep R Das, none declared.
Funding Information:
Grant support for the Dallas Heart Study was provided by the Donald W Reynolds Foundation and by USPHS GCRC [grant #M01-RR00633 from NIH/NCRR-CR]. MMP-9 measurements were performed at Alere, Inc. (San Diego, CA, USA), who also provided limited administrative support for the study.
PY - 2011/10
Y1 - 2011/10
N2 - Prior reports have associated increased circulating levels of matrix metalloproteinase-9 (MMP-9), an endopeptidase active in the extracellular matrix, with the formation and rupture of aortic aneurysms, raising the possibility that MMP-9 may be a useful diagnostic or therapeutic target for aortic pathology. However, associations between MMP-9 and pathological abdominal aortic phenotypes in the general population have not been reported. In the Dallas Heart Study, a population-based sample of Dallas County residents (n = 2304), we measured MMP-9 and performed magnetic resonance imaging (MRI) of the abdominal aorta, measuring aortic compliance, plaque, wall thickness and luminal diameter. After adjustment for traditional cardiac risk factors and body size, higher MMP-9 quartiles were independently associated with higher aortic wall thickness and larger luminal diameter (p < 0.0001 for each), but not abdominal aortic plaque (p = 0.08), coronary artery calcium (p = 0.20) or the aortic luminal diameter/aortic wall thickness ratio (p = 0.37), supporting the hypothesis that therapies targeting MMP-9 may affect the abdominal aortic wall and modify aortic pathology.
AB - Prior reports have associated increased circulating levels of matrix metalloproteinase-9 (MMP-9), an endopeptidase active in the extracellular matrix, with the formation and rupture of aortic aneurysms, raising the possibility that MMP-9 may be a useful diagnostic or therapeutic target for aortic pathology. However, associations between MMP-9 and pathological abdominal aortic phenotypes in the general population have not been reported. In the Dallas Heart Study, a population-based sample of Dallas County residents (n = 2304), we measured MMP-9 and performed magnetic resonance imaging (MRI) of the abdominal aorta, measuring aortic compliance, plaque, wall thickness and luminal diameter. After adjustment for traditional cardiac risk factors and body size, higher MMP-9 quartiles were independently associated with higher aortic wall thickness and larger luminal diameter (p < 0.0001 for each), but not abdominal aortic plaque (p = 0.08), coronary artery calcium (p = 0.20) or the aortic luminal diameter/aortic wall thickness ratio (p = 0.37), supporting the hypothesis that therapies targeting MMP-9 may affect the abdominal aortic wall and modify aortic pathology.
KW - aortic aneurysm
KW - aortic luminal diameter
KW - aortic wall thickness
KW - matrix metalloproteinase-9
UR - http://www.scopus.com/inward/record.url?scp=80054760669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054760669&partnerID=8YFLogxK
U2 - 10.1177/1358863X11422110
DO - 10.1177/1358863X11422110
M3 - Article
C2 - 22002999
AN - SCOPUS:80054760669
SN - 1358-863X
VL - 16
SP - 339
EP - 345
JO - Vascular Medicine
JF - Vascular Medicine
IS - 5
ER -